BUSINESS OVERVIEW
BenevolentAI (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery.
BenevolentAI is a leading developer of advanced artificial intelligence technologies that unlock the value of multimodal data, surface novel insights, and accelerate biomedical discovery
Through the combined capabilities of its AI platform, its scientific expertise, and wet-lab facilities, the Company is developing an inhouse drug pipeline of high-value assets. The Company is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.
Reports and presentations
Date and title | 16 Aug 2024 Investor Presentation August 2024 |
---|---|
Presentation | View |
Announcements
Financial calendar
19 September 2024
Interim Results for the six months ended 30 June 2024
|
EMAIL ALERTS
Get alerts for our announcements
Investor events, conference attendance and annual reporting.